VectorY raises €31 million in seed financing to develop next-generation gene therapies aimed at muscular and CNS disorders
Amsterdam, The Netherlands, 15 June 2021 – VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of muscular and neurodegenerative disorders through vectorized antibodies, today announces the...
VarmX appoints Dr. Jan Öhrström as CEO, and Dr. Alex Gold to Supervisory Board
Leiden, The Netherlands, 15 June 2021 - VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment of Dr. Jan Öhrström, as Chief Executive Officer, and of Dr. Alex Gold to the...
Confo Therapeutics Establishes Medical Advisory Board
Ghent, Belgium – June 10, 2021 - Confo Therapeutics today announced the establishment of its Medical Advisory Board (MAB). The MAB will provide external review and strategic advice for the company’s clinical development program including the future direction of...
CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer
Munich, Germany, May 4, 2021 – CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the appointment of Dr. Phil L’Huillier as Chief Executive Officer (CEO), effective May 17, 2021. Dr. Phil L’Huillier brings over two...
BGV Announces New Investment with i2020 Accelerator and Orbimed in Neurology-focused Therapeutics
Naarden, The Netherlands, 22 April 2021. - BioGeneration Ventures (BGV), together with i2020, an accelerator program backed by the San Diego-based venture company Torrey Pines Investment, and OrbiMed have announced a new startup investment in Brenig Therapeutics, a...
BGV Appoints Head of Communications
Naarden, The Netherlands, 16 April 2021 – BioGeneration Ventures (BGV), a leading early-stage VC in European biopharma has announced the appointment of Laura Asbjornsen as its Head of Communications. As lead for communications at both BGV and its platform partner...
How large pharma impacts biotechnology startup success – Nature Biotechnology
BGV's Daniela Couto and Gina Melcher von Dydiowa together with Sander van Deventer of Forbion published an article in Nature Biotechnology on pharma involvement in biotech startup success. Click on this link to read the whole article. Abstract: Many novel therapeutic...
Azafaros enters clinical stage with AZ-3102, an oral small molecule being developed for rare neurogenetic disorders
Phase 1 clinical study investigates safety and tolerability, pharmacokinetics and pharmacodynamic effects of first-in-class azasugar AZ-3102 in healthy subjects AZ-3102 is being initially developed for the treatment of patients suffering from GM1 and GM2...
Scenic Biotech Appoints Dr. Philippe Dro as Independent Chairman
Philippe Dro brings entrepreneurial expertise and biotech, medtech and pharma industry experience Successful serial entrepreneur with track record of growing companies, notably for Themis and Glycovaxyn Joins at a key juncture in Scenic Biotech’s strategic growth,...
CatalYm Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002 to Treat Patients with Checkpoint-Inhibitor Refractory Cancer
Munich, Germany, January 28, 2021 — CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, announced today the start of clinical development of CTL-002, its proprietary GDF-15 neutralizing antibody designed to enhance effector T cell entry...